Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fried

Showing results (371-380 of 383) with videos related to

Pageof 39
Sort By:
Hepatology Communications|November 6, 2023
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative studyAndrew M Moon, Sarah Cook, Rachel M Swier, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disordersC E Walsh, K Workowski, N A Terrault, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|December 4, 2024
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study designM Alan Brookhart, Tracy J Mayne, Charles Coombs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2014
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotypeMarc G Ghany, Robert Perrillo, Ruosha Li, et al.
The American Journal of Gastroenterology|January 4, 2023
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis BNorah A Terrault, Anna S Lok, Abdus S Wahed, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Pageof 39

Showing results (371-380 of 383) with videos related to

Sort By:
Pageof 39
Hepatology Communications|November 6, 2023
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative studyAndrew M Moon, Sarah Cook, Rachel M Swier, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disordersC E Walsh, K Workowski, N A Terrault, et al.
Alimentary Pharmacology & Therapeutics|October 30, 2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET databaseK R Reddy, J K Lim, A Kuo, et al.
Gastroenterology|August 12, 2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir TherapyAnna S Lok, Mark S Sulkowski, Jens J Kort, et al.
Hepatology (Baltimore, Md.)|December 4, 2024
Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study designM Alan Brookhart, Tracy J Mayne, Charles Coombs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 11, 2014
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotypeMarc G Ghany, Robert Perrillo, Ruosha Li, et al.
The American Journal of Gastroenterology|January 4, 2023
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis BNorah A Terrault, Anna S Lok, Abdus S Wahed, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Pageof 39